Liquidia (NASDAQ:LQDA) Insider Jason Adair Sells 688 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) insider Jason Adair sold 688 shares of the business’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $41.65, for a total transaction of $28,655.20. Following the completion of the sale, the insider directly owned 214,738 shares of the company’s stock, valued at approximately $8,943,837.70. The trade was a 0.32% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jason Adair also recently made the following trade(s):

• On Monday, April 13th, Jason Adair sold 7,301 shares of Liquidia stock. The stock was sold at an average price of $38.37, for a total transaction of $280,139.37.

Liquidia Price Performance

Shares of NASDAQ LQDA opened at $38.15 on Thursday. The firm has a market cap of $3.39 billion, a PE ratio of -45.96 and a beta of 0.45. The firm has a fifty day moving average of $36.38 and a 200 day moving average of $34.13. The company has a debt-to-equity ratio of 2.97, a quick ratio of 1.84 and a current ratio of 2.01. Liquidia Corporation has a one year low of $11.85 and a one year high of $46.67.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Thursday, March 5th. The company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.08 by $0.07. The company had revenue of $92.02 million during the quarter, compared to analyst estimates of $87.49 million. Liquidia had a negative net margin of 43.53% and a negative return on equity of 209.33%. The company’s revenue was up 3072.4% on a year-over-year basis. As a group, research analysts predict that Liquidia Corporation will post 1.75 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Federated Hermes Inc. acquired a new position in shares of Liquidia during the 3rd quarter valued at about $7,290,000. Caprock Group LLC acquired a new position in shares of Liquidia during the 3rd quarter valued at about $37,114,000. Farallon Capital Management LLC boosted its position in shares of Liquidia by 102.1% during the 3rd quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock valued at $194,783,000 after acquiring an additional 4,326,876 shares during the last quarter. Apis Capital Advisors LLC acquired a new position in shares of Liquidia during the 3rd quarter valued at about $9,569,000. Finally, Campbell & CO Investment Adviser LLC acquired a new position in shares of Liquidia during the 3rd quarter valued at about $2,026,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Raymond James Financial restated a “strong-buy” rating on shares of Liquidia in a research report on Thursday, March 5th. Wells Fargo & Company boosted their price target on shares of Liquidia from $44.00 to $51.00 and gave the stock an “overweight” rating in a research report on Monday, March 23rd. Zacks Research lowered shares of Liquidia from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 27th. Lifesci Capital upgraded shares of Liquidia to a “strong-buy” rating in a research report on Thursday, March 5th. Finally, HC Wainwright boosted their price target on shares of Liquidia from $50.00 to $55.00 and gave the stock a “buy” rating in a research report on Friday, March 6th. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $43.44.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).